Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with SclerodermaHANT, Faye N; LUDWICKA-BRADLEY, Anna; WANG, He-Jing et al.Journal of rheumatology. 2009, Vol 36, Num 4, pp 773-780, issn 0315-162X, 8 p.Article

Predicting Treatment Outcomes and Responder Subsets in Scleroderma-Related Interstitial Lung DiseaseROTH, Michael D; TSENG, Chi-Hong; ELASHOFF, Robert M et al.Arthritis and rheumatism. 2011, Vol 63, Num 9, pp 2797-2808, issn 0004-3591, 12 p.Article

High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung DiseaseGOLDIN, Jonathan G; LYNCH, David A; BROWN, Mathew S et al.Chest. 2008, Vol 134, Num 2, pp 358-367, issn 0012-3692, 10 p.Article

Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung DiseaseSTRANGE, Charlie; BOLSTER, Marcy B; SMITH, Edwin A et al.American journal of respiratory and critical care medicine. 2008, Vol 177, Num 1, pp 91-98, issn 1073-449X, 8 p.Article

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.American journal of respiratory and critical care medicine. 2007, Vol 176, Num 10, pp 1026-1034, issn 1073-449X, 9 p.Article

Cyclophosphamide versus placebo in scleroderma lung diseaseTASHKIN, Donald P; ELASHOFF, Robert; SEIBOLD, James R et al.The New England journal of medicine. 2006, Vol 354, Num 25, pp 2655-2666, issn 0028-4793, 12 p.Article